Abstract
Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.
Original language | English (US) |
---|---|
Pages (from-to) | 927-930 |
Number of pages | 4 |
Journal | Mayo Clinic proceedings |
Volume | 79 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2004 |
ASJC Scopus subject areas
- General Medicine